ORGANOGENESIS HOLDINGS INC

The current price of ORGO stock fluctuates throughout the trading day based on supply and demand. For the most accurate and up-to-date price, please refer to the live quote displayed at the top of this page. That figure reflects the latest trade and may include after-hours movement, depending on when you are viewing it.

Volatility describes how widely ORGO's price swings over time. Small-cap biotech stocks like ORGO often experience larger percentage moves than the broader market, especially around clinical trial updates or financing news. You can gauge historical volatility by reviewing the stock's beta, daily trading range, and 52-week price spread on this page.

Since ORGO is a clinical-stage biotech, traditional valuation metrics like P/E may not apply. Instead, consider its market capitalization, cash position, pipeline potential, and enterprise value. Analysts often use discounted cash flow or comparable company analysis. Review ORGO's latest financial statements and pipeline updates to form a view on its valuation.

Yes, ORGO can be traded in pre-market and after-hours sessions on U.S. exchanges, though liquidity is typically lower than during regular hours. Extended-hours trading allows reaction to news released outside 9:30 a.m. to 4:00 p.m. ET, but spreads may be wider and prices more volatile. Check with your broker for specific extended-hours rules.

ORGO does not currently pay dividends. The company is focused on advancing its clinical pipeline and likely reinvests any earnings or capital into research and development. Investors seeking income should note that many clinical-stage biotechs prioritize growth over shareholder distributions. For the latest dividend status, refer to the dividend section on this page.

Key risks for ORGO include clinical trial failures, regulatory setbacks, reliance on financing to fund operations, and competition in the biotech sector. As a small-cap company, its stock may be more volatile and less liquid than larger peers. Intellectual property disputes and changes in healthcare policy could also impact the business and share price.